Research Compendium/AOD-9604
Weight ManagementResearch OnlyNot For Human Consumption

AOD-9604

Anti-Obesity Drug 9604 · GH Fragment 177-191 · Fat Away peptide

GH C-terminal fragment with lipolytic activity and no anabolic or diabetogenic effects - the "Fat Away" research peptide.

MECHANISM OF ACTION

AOD-9604 is a synthetic 16-amino acid peptide corresponding to the C-terminal fragment of human growth hormone (amino acids 177–191), with an additional tyrosine added at the N-terminus for stability. It stimulates fat metabolism via β3-adrenergic receptor activation in adipocytes, promoting lipolysis without binding GHR (growth hormone receptor) - meaning it does not trigger IGF-1 elevation, anabolic effects, or glucose dysregulation. Originated from research at Monash University exploring which GH regions drove fat reduction vs. growth. Reached phase IIb/III clinical trials for obesity (Metabolic Pharmaceuticals) before funding was redirected.

RESEARCH APPLICATIONS

  • Adipose tissue lipolysis and fat mass reduction models
  • Selective fat metabolism without anabolic or diabetogenic effects
  • Obesity pharmacotherapy research (Metabolic Pharmaceuticals data)
  • Body composition recomposition research stacks (with Tesamorelin, MOTS-C)
  • GH fragment comparative pharmacology

RESEARCH HIGHLIGHTS

Selective Lipolysis Without IGF-1 Elevation

2001

Multiple studies confirm AOD-9604 stimulates lipolysis in fat cells via β3-adrenergic pathway without triggering GHR-mediated IGF-1 production - distinguishing it from GH itself.

Ref: Heffernan et al., Endocrinology

Phase IIb Obesity Trial Data

2004

24-week RCT (n=300+) demonstrated significant reduction in body fat percentage vs. placebo, with no adverse metabolic effects (fasting glucose, insulin sensitivity unchanged).

Ref: Metabolic Pharmaceuticals ASX

RESEARCH PROTOCOL NOTES

Research doses1–2 mg daily SC in clinical studies
Timing (studies)Pre-fasted administration to maximise lipolytic window
Stack contextFound in "Shredded" stack with MOTS-C + Tesamorelin
Available formatsVial (2–10mg), Pen (Fat Away)

Chemical Identity

Molecular FormulaC78H123N23O23S2
Molecular Weight1817.1 g/mol
CAS Number221231-10-3
Half-Life (t½)~30 minutes in plasma
SolubilitySoluble in water; bacteriostatic water preferred

Sequence

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Storage & Stability

Lyophilised: 2–8°C or -20°C. Reconstituted: 2–8°C, 28 days. More stable than many larger GH-related peptides.

Regulatory Status

Received GRAS (Generally Recognised As Safe) status from FDA for use as a food ingredient. Not approved as an injectable pharmaceutical. Not a GH secretagogue - does not bind GHR or elevate IGF-1. WADA: not explicitly listed on the prohibited list. SAHPRA: unscheduled research compound.

Back to Research CompendiumView Research Compounds →